Position :: Home -> Drug Database -> ripretinib

ripretinib

Drug Code : 2202132150

Drug Brand : Qinlock

Company : Deciphera Pharmaceuticals, LLC

Approved by : FDA, NMPA

Approval Time : May. 15, 2020

Direct Target : KIT,PDGFRA

Drug Type : Multi-target inhibitor

Gene : KIT

Alteration : p.V559A

Disease : Gastrointestinal Stromal Tumor

Indications : Ripretinib is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Mechanism Of Action :

Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.

Clinical Trial : NCT03353753

Dosage : The recommended dose of ripretinib was 150 mg orally once daily with or without food.

Reference Source :

Structure :

Related Targets and Diseases

Drug Name	Gene		Disease		Negative Genotypes	Drug Brand		Drug Type

Reference List :

Approval Notifications

Hot words